APIC produces active pharmaceutical ingredients (APIs), intermediates and investigational new drugs, along with fine chemicals and reagents.
The new manufacturing facility, located in a Neuland complex in Pashamylaram, Hyderabad, is the first facility that APIC has established outside Japan.
As part of the agreement signed in March2013, Neuland will be responsible for operating the manufacturing facilities dedicated to provide APIC with capacity for meeting the needs of its customers for pharmaceutical APIs and intermediates.
APIC president and CEO Kiyoshi Kondo said, "This facility will benefit our growing customer base by rapidly increasing our capacity to deliver high quality, competitively-priced APIs and intermediates in partnership with Neuland, a company with a long history of outstanding quality and regulatory excellence."
Neuland Labs chairman and managing director D.R. Rao said, "This arrangement allows APIC to expand their business in Japan in a timely and cost-effective way, while also helping to raise Neuland’s profile as a quality supplier of APIs and intermediates to the Japanese market."